Still Enriched By Partnership, Curis Faces Ongoing Risks In 2014
This article was originally published in The Pink Sheet Daily
The Lexington, Mass.-based oncology specialist seeks to resume enrollment in a Phase I trial halted after a patient death, while a revenue-generating drug partnered with Genentech could soon have a new competitor.
You may also be interested in...
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.